Clinical trial
A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma…
NCT00499239 · Gilead Sciences, Industry · Terminated
Key facts
| NCT number | NCT00499239 |
|---|---|
| Title | A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM) |
| Official title | Multi-center, Open-label, Dose-escalating Phase I/II Trial of GS-9219 Administered Once Every Three Weeks Intravenously to Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin's Lymphoma or Multiple Myeloma |
| Lead sponsor | Gilead Sciences, Industry |
| Status | Terminated |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma |
| Intervention type | Drug |
| Interventions | GS-9219 |
| Enrollment | 32 |
| Start date | Jul 1, 2007 |
| Primary completion | Jul 1, 2010 |
| Completion | Oct 1, 2010 |
| First posted | Jul 11, 2007 |
| Last update posted | Feb 4, 2014 |
| Countries | Czechia, Russia, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: